AKT1 and cancer: Evidence shows that p66Shc promotes chemoresistance through the PI3K/Akt pathway, which conveys anti‐apoptotic signals that protect cancer cells from chemotherapeutic drugs [22]; therefore, targeting p66Shc or its downstream effects could be a sensible strategy to improve treatment outcomes by overcoming such resistance mechanisms.